{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:41:46Z","timestamp":1790991706751,"version":"4.1.0"},"reference-count":108,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Paraproteinemic neuropathies represent an important subset of peripheral neuropathies. Once identified, further evaluation into the paraproteinemic subtype, clinical exam pattern, and electrodiagnostic phenotype helps clarify if the paraproteinemia is coincidental or causal of the neuropathy, as not all paraproteinemias cause neuropathy. Of all paraproteinemias, immunoglobulin M (IgM)-associated peripheral neuropathy, or IgM neuropathy, is of particular importance as half of IgM neuropathies also harbor anti-myelin-associated glycoprotein antibodies, which produce a characteristic demyelinating pattern on nerve conduction testing. Immunoglobulin G and immunoglobulin A paraproteinemias are less strongly associated with peripheral neuropathy, except in the setting of multiple myeloma or osteosclerotic myeloma (POEMS syndrome), which have characteristic systemic features. In multiple myeloma, chemotherapy is more likely to result in neuropathy than the myeloma itself. Finally, the presence of systemic features (e.g., cardiomyopathy, nephropathy, recurrent carpal tunnel syndrome, and autonomic insufficiency) should raise concern for hereditary or acquired light (AL) chain amyloidosis. AL amyloidosis can occur in the setting of any light or heavy chain paraproteinemia. Central to the proper evaluation of paraproteinemic neuropathy is electrodiagnostic testing, which helps delineate axonal versus demyelinating paraproteinemic neuropathy, the latter often misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy.<\/jats:p>","DOI":"10.1055\/s-0044-1791769","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T22:52:08Z","timestamp":1729205528000},"page":"099-111","source":"Crossref","is-referenced-by-count":3,"title":["Top 10 Clinical Pearls in Paraproteinemic Neuropathies"],"prefix":"10.1055","volume":"45","author":[{"given":"Benjamin","family":"Becker","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Medicine, Department of Neurology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Stino","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Medicine, Department of Neurology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12883-016-0532-4","article-title":"Paraproteinemic neuropathy: a practical review","volume":"16","author":"R A Rison","year":"2016","journal-title":"BMC Neurol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jcp.35.1.63","article-title":"Monoclonal gammopathies in the adult population of Finist\u00e8re, France","volume":"35","author":"J P Saleun","year":"1982","journal-title":"J Clin Pathol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9343(87)90375-5","article-title":"Evaluation of monoclonal gammopathies in the \u201cwell\u201d elderly","volume":"82","author":"J Crawford","year":"1987","journal-title":"Am J Med"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.41.8.1315","article-title":"Prevalence of peripheral neuropathy in the Parsi community of Bombay","volume":"41","author":"N E Bharucha","year":"1991","journal-title":"Neurology"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1212\/WNL.43.6.1115","article-title":"Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities","volume":"43","author":"G Savettieri","year":"1993","journal-title":"Neurology"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2337\/dc11-1108","article-title":"Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K","volume":"34","author":"C A Abbott","year":"2011","journal-title":"Diabetes Care"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1212\/WNL.45.10.1832","article-title":"Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample","volume":"45","author":"E M Beghi","year":"1995","journal-title":"Neurology"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","article-title":"Prevalence of monoclonal protein in peripheral neuropathy","volume":"31","author":"J J Kelly Jr","year":"1981","journal-title":"Neurology"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamaneurol.2014.1279","article-title":"Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy","volume":"71","author":"B C Callaghan","year":"2014","journal-title":"JAMA Neurol"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1468-1331.2011.03380.x","article-title":"Neuropathy and paraproteins: review of a complex association","volume":"18","author":"Y A Rajabally","year":"2011","journal-title":"Eur J Neurol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision","volume":"26","author":"P YK Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1007\/s10072-021-05583-7","article-title":"Paraproteinemia and neuropathy","volume":"42","author":"H Koike","year":"2021","journal-title":"Neurol Sci"},{"issue":"05","key":"ref13","first-page":"1492","article-title":"Paraproteinemic neuropathies","volume":"29","author":"S R Beydoun","year":"2023","journal-title":"Continuum (Minneap Minn)"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ana.410300111","article-title":"Neuropathy associated with monoclonal gammopathies of undetermined significance","volume":"30","author":"S Gosselin","year":"1991","journal-title":"Ann Neurol"},{"issue":"05","key":"ref15","first-page":"1369","article-title":"Peripheral neuropathies associated with monoclonal gammopathies","volume":"26","author":"E Naddaf","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"R A Kyle","year":"2003","journal-title":"Blood"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"S V Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"R A Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"R A Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"ref21","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.3390\/cancers14215247","article-title":"Monoclonal gammopathies of clinical significance: a critical appraisal","volume":"14","author":"R R\u00edos-Tamayo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"R S Go","year":"2018","journal-title":"Blood"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1464-5491.1989.tb01133.x","article-title":"Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population","volume":"6","author":"H A Neil","year":"1989","journal-title":"Diabet Med"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","article-title":"Monoclonal gammopathy of undetermined significance: a consensus statement","volume":"150","author":"J R Berenson","year":"2010","journal-title":"Br J Haematol"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2009.07807.x","article-title":"UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)","volume":"147","author":"J Bird","year":"2009","journal-title":"Br J Haematol"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"N W van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pmrj.2008.11.010","article-title":"Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"1","author":"J D England","year":"2009","journal-title":"PM R"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"A Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/clinchem\/34.8.1633","article-title":"Sensitivity of immunofixation electrophoresis for detecting IgM paraproteins in serum","volume":"34","author":"S N Kahn","year":"1988","journal-title":"Clin Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clinbiochem.2017.05.001","article-title":"Laboratory testing for monoclonal gammopathies: focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"51","author":"M AV Willrich","year":"2018","journal-title":"Clin Biochem"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"J A Katzmann","year":"2009","journal-title":"Clin Chem"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1373\/clinchem.2004.046870","article-title":"Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice","volume":"51","author":"J A Katzmann","year":"2005","journal-title":"Clin Chem"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"T E Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11910-011-0237-4","article-title":"An update on monoclonal gammopathy and neuropathy","volume":"12","author":"S Ramchandren","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00319857","article-title":"The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings","volume":"238","author":"K B Yeung","year":"1991","journal-title":"J Neurol"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0404.1992.tb06033.x","article-title":"Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies","volume":"85","author":"E Nobile-Orazio","year":"1992","journal-title":"Acta Neurol Scand"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/practneurol-2020-002837","article-title":"Paraproteinaemic neuropathy: MGUS and beyond","volume":"21","author":"A S Carroll","year":"2021","journal-title":"Pract Neurol"},{"issue":"02","key":"ref38","first-page":"94","article-title":"The challenge of distinguishing POEMS from chronic inflammatory demyelinating polyneuropathy - importance of early recognition and diagnosis of POEMS","volume":"14","author":"F Chow","year":"2018","journal-title":"US Neurol"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp-2011-301706","article-title":"Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy","volume":"83","author":"S Nasu","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.20678","article-title":"Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins","volume":"35","author":"V D Lupu","year":"2007","journal-title":"Muscle Nerve"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/mus.1145","article-title":"Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody","volume":"24","author":"D Cocito","year":"2001","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.22229","article-title":"Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy","volume":"45","author":"S Mathis","year":"2012","journal-title":"Muscle Nerve"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jns.12451","article-title":"The neuropathy in hereditary transthyretin amyloidosis: a narrative review","volume":"26","author":"S Tozza","year":"2021","journal-title":"J Peripher Nerv Syst"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S0317167100011483","article-title":"The neuropathies of Waldenstr\u00f6m's macroglobulinemia (WM) and IgM-MGUS","volume":"38","author":"C J Klein","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"101129","DOI":"10.1016\/j.blre.2023.101129","article-title":"Current approach to Waldenstr\u00f6m macroglobulinemia","volume":"62","author":"P Kapoor","year":"2023","journal-title":"Blood Rev"},{"issue":"21","key":"ref46","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies","volume":"136","author":"M Le Cann","year":"2020","journal-title":"Blood"},{"issue":"06","key":"ref47","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s00415-018-8853-4","article-title":"CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA)","volume":"265","author":"R Garcia-Santibanez","year":"2018","journal-title":"J Neurol"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/01.wco.0000245368.36576.0d","article-title":"Anti-myelin-associated glycoprotein neuropathy","volume":"19","author":"A J Steck","year":"2006","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"ref49","first-page":"1065","article-title":"230th ENMC International Workshop: Improving future assessment and research in IgM anti-MAG peripheral neuropathy: a consensus collaborative effort, Naarden, the Netherlands, 24-26 February 2017","volume":"27","author":"M HJ Pruppers","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jnen\/64.5.386","article-title":"IgG neuropathy: an immunoelectron microscopic study","volume":"64","author":"J M Vallat","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/1531-8249(200006)47:6<808::AID-ANA15>3.0.CO;2-8","article-title":"Myelin widenings and MGUS-IgA: an immunoelectron microscopic study","volume":"47","author":"J M Vallat","year":"2000","journal-title":"Ann Neurol"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ana.410360313","article-title":"Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy","volume":"36","author":"E Nobile-Orazio","year":"1994","journal-title":"Ann Neurol"},{"issue":"S 01","key":"ref53","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1002\/ana.410370705","article-title":"Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies","volume":"37","author":"N Latov","year":"1995","journal-title":"Ann Neurol"},{"issue":"09","key":"ref54","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/14737175.2016.1198257","article-title":"Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies","volume":"16","author":"J M Vallat","year":"2016","journal-title":"Expert Rev Neurother"},{"issue":"05","key":"ref55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","article-title":"Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features","volume":"89","author":"J Svahn","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies","volume":"123","author":"E Nobile-Orazio","year":"2000","journal-title":"Brain"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/mus.27954","article-title":"Anti-myelin-associated glycoprotein neuropathy: Where do we stand?","volume":"68","author":"A M Stino","year":"2023","journal-title":"Muscle Nerve"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"M C Dalakas","year":"2009","journal-title":"Ann Neurol"},{"issue":"24","key":"ref59","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"J M L\u00e9ger","year":"2013","journal-title":"Neurology"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/mus.1069","article-title":"Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy","volume":"24","author":"K C Gorson","year":"2001","journal-title":"Muscle Nerve"},{"issue":"10","key":"ref61","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","article-title":"A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy","volume":"249","author":"G Comi","year":"2002","journal-title":"J Neurol"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"M C Dalakas","year":"1996","journal-title":"Ann Neurol"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.neurol.2011.04.005","article-title":"Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study","volume":"167","author":"M Th\u00e9audin","year":"2011","journal-title":"Rev Neurol (Paris)"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"653734","DOI":"10.3389\/fneur.2021.653734","article-title":"Treatment approaches for atypical CIDP","volume":"12","author":"D Menon","year":"2021","journal-title":"Front Neurol"},{"issue":"05","key":"ref65","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0039-1688994","article-title":"Neuropathy associated with systemic amyloidosis","volume":"39","author":"M Kaku","year":"2019","journal-title":"Semin Neurol"},{"issue":"05","key":"ref66","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0025-6196(11)65130-6","article-title":"Amyloidosis: recognition, confirmation, prognosis, and therapy","volume":"74","author":"M A Gertz","year":"1999","journal-title":"Mayo Clin Proc"},{"issue":"04","key":"ref67","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1468-1331.2010.03215.x","article-title":"Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study","volume":"18","author":"M Matsuda","year":"2011","journal-title":"Eur J Neurol"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/archinte.1989.00390020080016","article-title":"Peripheral neuropathy as an early marker of AL amyloidosis","volume":"149","author":"M A Duston","year":"1989","journal-title":"Arch Intern Med"},{"issue":"01","key":"ref69","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"R A Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.410060102","article-title":"The natural history of peripheral neuropathy in primary systemic amyloidosis","volume":"6","author":"J J Kelly Jr","year":"1979","journal-title":"Ann Neurol"},{"issue":"03","key":"ref71","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"E Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"09","key":"ref72","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0025-6196(12)62409-4","article-title":"Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart","volume":"59","author":"L Cueto-Garcia","year":"1984","journal-title":"Mayo Clin Proc"},{"issue":"08","key":"ref73","first-page":"813","article-title":"AL amyloidosis: unfolding a complex disease","volume":"10","author":"R Lu","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"01","key":"ref74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"V Sanchorawala","year":"2022","journal-title":"Amyloid"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"A D Wechalekar","year":"2023","journal-title":"Amyloid"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1081098","DOI":"10.3389\/fcvm.2022.1081098","article-title":"Amyloidosis: What does pathology offer? The evolving field of tissue biopsy","volume":"9","author":"M Riefolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"06","key":"ref77","first-page":"706","article-title":"Selection of biopsy site for patients with systematic amyloidosis","volume":"38","author":"C L Zhang","year":"2016","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"issue":"12","key":"ref78","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/acn3.51924","article-title":"Amyloid detection and typing yield of skin biopsy in systemic amyloidosis and polyneuropathy","volume":"10","author":"S Pinton","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"ref79","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"N M Fine","year":"2014","journal-title":"Am J Cardiol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2017.11.001","article-title":"Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis","volume":"72","author":"Y Garcia","year":"2018","journal-title":"Hum Pathol"},{"issue":"05","key":"ref81","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00000441-196605000-00001","article-title":"Value of rectal biopsy in the diagnosis of primary systemic amyloidosis","volume":"251","author":"R A Kyle","year":"1966","journal-title":"Am J Med Sci"},{"issue":"04","key":"ref82","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/13506120903421850","article-title":"Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type","volume":"16","author":"B Do Amaral","year":"2009","journal-title":"Amyloid"},{"issue":"05","key":"ref83","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/art.1780360518","article-title":"Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients","volume":"36","author":"E Hachulla","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00277-015-2549-y","article-title":"Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis","volume":"95","author":"T Suzuki","year":"2016","journal-title":"Ann Hematol"},{"issue":"05","key":"ref85","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-018-0080-9","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018","volume":"8","author":"M A Gertz","year":"2018","journal-title":"Blood Cancer J"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis","volume":"141","author":"I Vaxman","year":"2019","journal-title":"Acta Haematol"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjh.14205","article-title":"Natural history of amyloidosis isolated to fat and bone marrow aspirate","volume":"179","author":"R Chakraborty","year":"2017","journal-title":"Br J Haematol"},{"issue":"01","key":"ref88","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1212\/WNL.31.1.24","article-title":"The spectrum of peripheral neuropathy in myeloma","volume":"31","author":"J J Kelly Jr","year":"1981","journal-title":"Neurology"},{"issue":"05","key":"ref89","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/archneur.1971.00490050038003","article-title":"The neuropathy of multiple myeloma. An electrophysiological and histological study","volume":"25","author":"J C Walsh","year":"1971","journal-title":"Arch Neurol"},{"issue":"11","key":"ref90","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3109\/10428194.2011.598253","article-title":"Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis","volume":"52","author":"P Malhotra","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"P G Richardson","year":"2012","journal-title":"Leukemia"},{"issue":"08","key":"ref92","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"S V Rajkumar","year":"2001","journal-title":"Leukemia"},{"issue":"21","key":"ref93","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"S V Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref94","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"D Siegel","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"ref95","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.0000000000003093","article-title":"Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study","volume":"87","author":"C Dalla Torre","year":"2016","journal-title":"Neurology"},{"issue":"08","key":"ref96","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"M A Dimopoulos","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"ref97","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"P G Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref98","first-page":"1307","article-title":"Paraproteinemic neuropathies","volume":"20","author":"M L Mauermann","year":"2014","journal-title":"Continuum (Minneap Minn)"},{"issue":"09","key":"ref99","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jamaoncol.2021.0586","article-title":"Update on the diagnosis and treatment of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome: a review","volume":"7","author":"J Khouri","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"ref100","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1212\/WNL.0000000000008062","article-title":"Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey","volume":"93","author":"T Suichi","year":"2019","journal-title":"Neurology"},{"issue":"07","key":"ref101","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ajh.25495","article-title":"POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"A Dispenzieri","year":"2019","journal-title":"Am J Hematol"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00415-018-9068-4","article-title":"An update on the diagnosis and management of the polyneuropathy of POEMS syndrome","volume":"266","author":"F Cerri","year":"2019","journal-title":"J Neurol"},{"issue":"24","key":"ref103","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1182\/blood-2010-12-328112","article-title":"Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome","volume":"117","author":"J Li","year":"2011","journal-title":"Blood"},{"issue":"01","key":"ref104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12295","article-title":"Peripheral nervous system involvement in lymphomas","volume":"24","author":"C Briani","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"24","key":"ref105","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1182\/blood-2009-12-258210","article-title":"Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report","volume":"115","author":"S Grisariu","year":"2010","journal-title":"Blood"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"935936","DOI":"10.3389\/fneur.2022.935936","article-title":"Multidisciplinary amyloidosis care in the era of personalized medicine","volume":"13","author":"N Bumma","year":"2022","journal-title":"Front Neurol"},{"issue":"01","key":"ref107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11899-021-00646-0","article-title":"Multidisciplinary approach to older adults with hematologic malignancies - a paradigm shift","volume":"17","author":"S A Wall","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"ref108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"M V Mateos","year":"2020","journal-title":"Blood Cancer J"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T23:31:49Z","timestamp":1737156709000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":108,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791769","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}